Trinity Biotech Announces It Has Begun Shipments of Its New HIV Screening Test, TrinScreen HIV to Kenya
December 27 2023 - 7:57AM
Trinity Biotech plc (Nasdaq: TRIB) (the “Company”), a leading
developer and manufacturer of diagnostic products for the
point-of-care and clinical laboratory markets, today announces it
has begun commercial shipments to Kenya of its new rapid HIV
screening test, TrinScreen HIV.
The Kenyan HIV screening programme is one of the
largest in Africa, with an estimated 10 million HIV screening tests
performed annually. The Company has begun commercial shipments as
part of the initial purchase order the Company received for 2.5
million tests, with further shipments under that purchase order
scheduled for early 2024. Trinity understands that the Kenyan
Ministry of Health has received commitments from all relevant
sponsors (including Global Fund and USAID) to fund the procurement
from the Company of all 10 million rapid screening HIV tests
required by Kenya for 2024, and the Company expects to receive and
fill additional purchase orders during 2024. The implementation of
the new HIV testing algorithm, that includes TrinScreen HIV, is
expected to start in January 2024.
“We are pleased to announce we have commenced
shipments of TrinScreen HIV to Kenya, which is a major milestone
for Trinity Biotech, who has been a key player in providing HIV
tests to Africa for many years,” said John Gillard, Chief Executive
Officer. “Several other countries in Africa are adopting the
revised WHO guidelines which prompted the update in the Kenyan HIV
testing algorithm. This adoption by Kenya is an endorsement of our
new product, TrinScreen HIV, and provides Trinity Biotech with a
significant opportunity to penetrate deeper into the HIV screening
market across all of Africa. The total estimate for the global HIV
screening market is 150 million tests annually, with the majority
of testing conducted in sub-Saharan Africa.”
Forward Looking Statements
Certain statements made in this release that are
not historical are forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. The words
“estimate”, “project”, “intend”, “expect”, “believe” and similar
expressions are intended to identify forward-looking statements.
These forward-looking statements involve known and unknown risks
and uncertainties. Many factors could cause the actual results,
performance or achievements of Trinity Biotech to be materially
different from any future results, performance or achievements that
may be expressed or implied by such forward-looking statements,
including, but not limited to, the results of research and
development efforts, the effect of regulation by the U.S. Food and
Drug Administration and other agencies, the impact of competitive
products, product development commercialization, continued listing
on the Nasdaq Stock Market and technological difficulties. For
additional information regarding these and other risks and
uncertainties associated with Trinity Biotech’s business, reference
is made to our reports filed from time to time with the U.S.
Securities and Exchange Commission. We undertake no obligation to
update or revise any forward-looking statements for any reason.
About Trinity Biotech Plc
Trinity Biotech develops, acquires, manufactures
and markets diagnostic systems, including both reagents and
instrumentation, for the point-of-care and clinical laboratory
segments of the diagnostic market. The products are used to detect
infectious diseases and to quantify the level of Haemoglobin A1c
and other chemistry parameters in serum, plasma and whole blood.
Trinity Biotech sells direct in the United States, Germany, France
and the U.K. and through a network of international distributors
and strategic partners in over 75 countries worldwide. For further
information, please see the Company's website:
www.trinitybiotech.com.
Contact: |
Trinity Biotech plc |
LifeSci Advisors, LLC |
|
Mícheál Roche |
Eric Ribner |
|
(353)-1-2769800 |
(1)-646-751-4363 |
|
|
E-mail:
investorrelations@trinitybiotech.com |
Trinity Biotech (NASDAQ:TRIB)
Historical Stock Chart
From Apr 2024 to May 2024
Trinity Biotech (NASDAQ:TRIB)
Historical Stock Chart
From May 2023 to May 2024